TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30413407
Drug: Alpelisib plus
Normalized name: alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib plus fulvestrant endocrine therapy
Study: 28628843
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and chemoradiotherapy (CRT)
Study: 22984204
Drug: Levofloxacin-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-containing quadruple therapy (EBTL group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of levofloxacin once daily for 10 days (n = 76)
Study: 22984204
Drug: High-dose metronidazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metronidazole-based quadruple therapy (EBTM group): 40 mg of esomeprazole twice daily, 300 mg of bismuth subcitrate four times daily, 500 mg of tetracycline four times daily, and 500 mg of metronidazole four times daily for 10 days (n = 74)
Study: 22984204
Drug: Levofloxacin-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-containing quadruple therapy (EBTL group)
Study: 22984204
Drug: High-dose metronidazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metronidazole-based quadruple therapy (EBTM group)
Study: 22073795
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (60 mg elemental iron)
Study: 15046441
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (historical control group)
Study: 8915150
Drug: Diphencyprone (DPCP)
DrugBank: Diphencyprone (DB12173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphencyprone (DPCP) treatment, 2% solution, applied once a week for at least 3 months, up to 1 year.
Study: 1347854
Drug: Artesunate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (600 mg over 5 days)
Study: 1347854
Drug: Mefloquine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (750 mg then 500 mg 6 h later)
Study: 8701045
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of artesunate and mefloquine
Study: 2859204
Drug: Triprolidine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine (2.5 mg and 5 mg)
Study: 2957398
Drug: Isotretinoin 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.05% gel
Study: 11132613
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg o.d. (n = 15)
Study: 11132613
Drug: Felodipine 5-10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5-10 mg o.d. (n = 15)
Study: 11132613
Drug: Lacidipine 4-6
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4-6 mg o.d. (n = 15)
Study: 11132613
Drug: Manidipine 10-20
Normalized name: manidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10-20 mg o.d. (n = 15)
Study: 9163255
Drug: Furosemide-containing suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide-containing suppositories (Massa Estarinum 299)
Study: 9163255
Drug: Furosemide Sodium
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide Sodium suppositories
Study: 1590228
Drug: Pirenzepine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (2 mg)
Study: 1590228
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (2 ml)
Study: 28765003
Drug: Vaccine (VAC)
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (VAC)
Study: 15190963
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of a monoclonal anti-IL-6 Ab (B-E8)
Study: 11477830
Drug: Acanthopanax Injection
Normalized name: Manyprickle Acanthopanax
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acanthopanax Injection (AI) 60-80 ml added to 500 ml of 0.9% normal saline, given intravenously once a day for 14 days
Study: 11477830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 500 ml of dextra-40 given intravenously once a day for 14 days
Study: 11477830
Drug: Acanthopanax Injection
Normalized name: Manyprickle Acanthopanax
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acanthopanax Injection (AI) 10 ml given intravenously once daily for 7 days in rabbit model
Study: 11477830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 10 ml of normal saline given intravenously once daily for 7 days in rabbit model
Study: 8681496
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g x 3 for two weeks)
Study: 8681496
Drug: Propafenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (300 mg x 3 for two weeks)
Study: 8681496
Drug: Propafenone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone + L-carnitine (300 mg x 3 + 2 g x 3 at the second week)
Study: 8681496
Drug: Mexiletine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (200 mg x 3 for two weeks)
Study: 8681496
Drug: Mexiletine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine + L-carnitine (200 mg x 3 + 2 g x 3 at the second week)
Study: 31633865
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg controlled-release oral morphine
Study: 28698334
Drug: Monthly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly text messages reminding them to test for HIV/STIs
Study: 26504123
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture combined with pharmacological therapy (morphine and phenobarbital)
Study: 12793117
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (pharmacological therapy alone)
Study: 15548314
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 25 mg base/kg
Study: 15548314
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) 1.25/25 mg/kg
Study: 15548314
Drug: Mefloquine (M)
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine (M) 15 mg base/kg
Study: 15548314
Drug: Mefloquine-artesunate (MA)
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine-artesunate (MA) 15:4 mg/kg
Study: 7833227
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg orally three times a day for 6 days followed by 7.5 mg zopiclone
Study: 2901220
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg vs Ranitidine 300 mg
Study: 2901220
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg vs Famotidine 40 mg
Study: 28830555
Drug: Work-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-focused cognitive behavioral therapy (6 sessions) and a small workplace intervention
Study: 25297643
Drug: Prophylactic vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic vitamin K (single dose)
Study: 21372622
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy (CBGT) added to Treatment as Usual (TAU)
Study: 18081756
Drug: Oral Language
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Language (OL) programme
Study: 10833090
Drug: Pan+Amo+Cla (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pan+Amo+Cla (40 mg b.i.d. Pantoprazole, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Study: 10833090
Drug: RBC+Amo+Cla (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC+Amo+Cla (400 mg b.i.d. Ranitidine bismuth citrate, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Study: 7979074
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine 75 mg, clonidine 150 micrograms, and diamorphine 5 mg in 60 ml normal saline at 1-4 ml/h for 24-48 hours preoperatively and maintained for at least 3 days postoperatively
Study: 7979074
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine, clonidine, and diamorphine
Study: 776537
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg flupenthixol 2 to 4-times daily for 2 weeks
Study: 776537
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablets 2 to 4-times daily for 2 weeks
Study: 25040180
Drug: CLNP/BPO 3·0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLNP/BPO 3·0% twice daily
Study: 25040180
Drug: CLNP/BPO 3·0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLNP/BPO 3·0% once daily
Study: 23224626
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg/day) and vitamin D (60,000 IU/3 months)
Study: 23224626
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg/day), vitamin D (60,000 IU/3 months), and zinc (as per Indian Recommended Allowance)
Study: 11295650
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 microg twice daily for 6 weeks)
Study: 7498360
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEpo) treatment; specific dosage and duration not mentioned.
Study: 7498360
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group); 12 patients without PB CFU-E.
Study: 7498360
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of PB CFU-E; no specific treatment mentioned.
Study: 2023754
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy (prednisolone acetate 1% drops hourly and a single intravenous pulse of 500 mg methylprednisolone)
Study: 2023754
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (same topical therapy plus oral prednisone 60 to 80 mg daily)
Study: 2023754
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy (for patients treated early, less than or equal to 8 days)
Study: 2023754
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy (for patients treated early, less than or equal to 8 days)
Study: 7032681
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum combined with radiation therapy (4 mg/m2 into tumor-bearing lymph nodes and 2, 2, 4, 4, and 4 mg/m2 intravenously at specified days)
Study: 21289525
Drug: Bazedoxifene 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 5 mg
Study: 21289525
Drug: Bazedoxifene 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 10 mg
Study: 18777173
Drug: Topical miconazole
Normalized name: miconazole Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical miconazole oral gel (85 mg x 3, 3 days)
Study: 18777173
Drug: Oral voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral voriconazole (400 mg x 2, 1st day, 200 mg x 2, 2nd day)
Study: 17725472
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy plus exercise
Study: 14747427
Drug: Aripiprazole 5
Normalized name: aripiprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 5 mg, 10 mg, 15 mg, 20 mg once daily (Study 1)
Study: 14747427
Drug: Aripiprazole titrated
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole titrated from 10 to 30 mg/day (Study 2)
Study: 11393383
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg daily
Study: 11393383
Drug: Spirapril 3
Normalized name: spirapril 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 3 mg and Isradipine 2.5 mg daily
Study: 11393383
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Spirapril and Isradipine)
Study: 332217
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg xipamid
Study: 332217
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg xipamid
Study: 31811128
Drug: Supervised high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised high-dose primaquine
Study: 28941934
Drug: Nitrate supplementation
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate supplementation (140 ml of concentrated beetroot juice)
Study: 1761065
Drug: Verapamil administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil administration
Study: 15553660
Drug: Erdosteine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (300 mg b.i.d. for 8 months)
Study: 11761117
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group (168‐255 microg of each phthalate)
Study: 11761117
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose group (336 to 510 microg of each phthalate)
Study: 11761117
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dose)
Study: 9247840
Drug: Cimetidine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1,000 mg daily over 20 days
Study: 9247840
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment with metamizol doses of 750 mg and 1,500 mg
Study: 7506164
Drug: nimesulide (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (200mg twice daily)
Study: 7506164
Drug: ketoprofen (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen (100mg twice daily)
Study: 2428719
Drug: Depot secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depot secretin therapy (800 CU by subcutaneous injection twice daily for 7 days)
Study: 26179237
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg alone under fasting conditions
Study: 26179237
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg after a high-fat, high-calorie meal
Study: 26179237
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg coadministered with rabeprazole 40 mg under fasting conditions
Study: 19641362
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily for 2 weeks
Study: 17848492
Drug: Novel clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel clinical trial design (sequential parallel design)
Study: 11406729
Drug: Warfarin 1
Normalized name: warfarin 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 1 mg
Study: 11406729
Drug: Warfarin 2
Normalized name: warfarin 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 2 mg
Study: 11406729
Drug: Warfarin 3
Normalized name: warfarin 3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 3 mg
Study: 9720470
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg/day for 10 days)
Study: 9720470
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (30 mg/kg/day for 10 days)
Study: 3053887
Drug: Lactitol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (10 g/6 h)
Study: 3053887
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 ml/6 h, 66% w/v, containing 10 g of lactulose)
Study: 7142087
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 500 mg cefadroxil
Study: 7142087
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1 g cefadroxil
Study: 7142087
Drug: Three repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three repeated doses of 500 mg cefadroxil
Study: 7142087
Drug: Two repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two repeated doses of 1 g cefadroxil
Study: 24799467
Drug: Control immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control immunotherapy (KLH plus GM-CSF)
Study: 22691628
Drug: Masitinib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib (3 to 6 mg/kg/day for at least 12 months)
Study: 17545861
Drug: Sublingual house
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual house dust-mite-specific immunotherapy for 2 years followed by 1 year of placebo (Group A)
Study: 17545861
Drug: Sublingual house
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual house dust-mite-specific immunotherapy for 3 years (Group B)
Study: 14991953
Drug: OAC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC (omeprazole 20 mg + amoxicillin 1 000 mg + clarithromycin 250 mg)
Study: 14991953
Drug: OFC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFC (omeprazole 20 mg + furazolidone 100 mg + clarithromycin 250 mg)
Study: 14991953
Drug: OMC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMC (omeprazole 20 mg + metronidazole 200 mg + clarithromycin 250 mg)
Study: 14991953
Drug: OFA (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFA (omeprazole 20 mg + furazolidone 100 mg + amoxicillin 1 000 mg)
Study: 28591155
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg orally twice daily for five days)
Study: 25957214
Drug: Prophylaxis antibiotics
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis antibiotics
Study: 24166282
Drug: Weekly ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly ixabepilone 16 mg/m2 as a 1-h IV infusion weekly on days 1, 8, and 15 of a 28-day cycle (1 week off therapy); n=85
Study: 24166282
Drug: Every-3-week ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every-3-week ixabepilone 40 mg/m2 as a 3-h IV infusion on day 1 of a 21-day cycle; n=91
Study: 21749265
Drug: Tilting Whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilting Whole Body Vibration therapy (WBV) for 12 weeks (12.5-Hz frequency; 3-mm amplitude)
Study: 23370417
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg)
Study: 17544776
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PDT with verteporfin and intravitreal bevacizumab
Study: 15215482
Drug: Topical alpha-lactalbumin-oleic
Normalized name: alpha-lactalbumin (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alpha-lactalbumin-oleic acid
Study: 15215482
Drug: Topical alpha-lactalbumin-oleic
Normalized name: alpha-lactalbumin (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alpha-lactalbumin-oleic acid (second phase)
Study: 15215482
Drug: Topical alpha-lactalbumin-oleic
Normalized name: alpha-lactalbumin (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical alpha-lactalbumin-oleic acid (long-term follow-up)
Study: 8090391
Drug: Prophylactic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic saline amnioinfusion (600‐mL bolus followed by 3 mL/minute)
Study: 21474494
Drug: Individual music
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual music therapy plus standard care (20 bi‐weekly sessions)
Study: 18284437
Drug: PF‐00734200 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00734200 (0.3 to 300 mg)
Study: 18284437
Drug: PF‐00734200 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐00734200 (10 mg)
Study: 10839878
Drug: EMLA patch
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA patch (5%‐1 g)
Study: 8401013
Drug: 15 mmol
Normalized name: dibasic potassium phosphate 15 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mmol magnesium hydroxide daily for one year